Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7680MR)

This product GTTS-WQ7680MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in B-cell malignancies research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7680MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ486MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ13241MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ7921MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ13613MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ11478MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ794MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ4448MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ5090MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW